Novo Seeds co-led a $61.7m round for the oncology therapy developer to help commercialise research originating at University of Copenhagen and Rigshospitalet.

Adcendo, a Denmark-based antibody drug conjugate (ADC) developer based on research at University of Copenhagen and Rigshospitalet, completed a €51m ($61.7m) series A round yesterday co-led by pharmaceutical firm Novo through its Novo Seeds subsidiary.
Venture capital firm Ysios Capital co-led the round, which also featured investment management firm RA Capital Management, VC firm HealthCap and healthcare investment firm Gilde Healthcare.
Adcendo is developing ADCs intended to treat cancer, and its drug candidates are targeting the uPARAP cell-surface…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?